Velpacee - Tablet Sofosbuvir + Velpatasvir - 400mg+100mg 7 Tablet(s) / Box Jenphar Bangladesh Ltd. Introduction: Velpacee is a combination of two antiviral medicines. This prescription medicine is used in the treatment of chronic hepatitis C virus (HCV) infection. It fights against the viruses to resolve the infection. Velpacee should be taken in the prescribed dose and duration. It can be taken with or without food, but take it at the same time daily. It is advised not to consume more than the recommended dose. It is important to inform your doctor if you have any health conditions such as liver or kidney disease. It is harmful to consume alcohol along with this medicine, so it... Uses of Velpacee: Chronic hepatitis C virus (HCV) infection Side effects of Velpacee: HeadacheTiredness How to use Velpacee: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Velpacee may be taken with or without food, but it is better to take it at a fixed time. How Velpacee works: Velpacee is a combination of two antiviral medicines: Sofosbuvir and Velpatasvir. They work by lowering the amount of hepatitis C virus in the body and removing the virus from the blood over a period of time. Indication: Chronic Hepatitis C Administration: May be taken with or without food Adult Dose: Oral Adult Chronic Hepatitis C Indicated for adults with chronic hepatitis C virus (HCV) infection genotypes 1, 2, 3, 4, 5, and 6 1 tablet (400 mg sofosbuvir/ 100 mg velpatasvir) qDay Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Sofosbuvir/velpatasvir for 12 weeks Patients with decompensated cirrhosis (Child-Pugh B or C): Sofosbuvir/velpatasvir plus weight-based ribavirin with food for 12 weeks Hepatic impairment Mild, moderate, or severe (Child-Pugh A, B, or C): No dosage adjustment required Child Dose: Safety and efficacy not established Renal Dose: Renal impairment Severe renal impairment (eGFR <30mL/min/1.73 m²) or ESRD: No dosage recommendation can be give owing to higher exposures (up to 20-fold) of the predominant sofosbuvir metabolite Contraindication: Hypersensitivity. Mode of Action: Sofosbuvir: Inhibitor of HCV NS5B RNA-dependent polymerase; its inhibition, in turn, suppresses viral replication Velpatasvir: Pangenotypic HCV NS5A inhibitor; the NS5A protein is required for viral replication Precaution: Direct-acting antivirals (DDAs) may reactivate hepatitis B virus (HBV) in patients who have a current or previous HBV infection while being treated for hepatitis C virus In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death Patients should be screened for evidence of current or prior HBV infection before starting treatment with DAAs, and monitored for HBV flare-ups or reactivation during DAA treatment and posttreatment follow-up Serious symptomatic bradycardia may occur if sofosbuvir is coadministered with amiodarone in combination with another direct-acting antiviral (eg, daclatasvir, simeprevir) Lactation: Unknown if sofosbuvir, velpatasvir,... Side Effect: >10% Without cirrhosis or with compensated cirrhosis Headache (22%),Fatigue (15%) With decompensated cirrhosis Fatigue (32%),Anemia (26%),Hemoglobin 3 x ULN (3%),Rash (2%),Depression (1%),Increased creatinine kinase >10 x ULN (1%) With decompensated cirrhosis Diarrhea (10%) Hemoglobin <3.5 g/dL (7%),Rash (5%),Increased creatinine kinase ≥10 x ULN (2%) Interaction: Coadministration with drugs that increase gastric pH are expected to decrease velpatasvir serum concentration